Trial Profile
Evaluation of the vaccine candidate CIGB-230 in individuals with chronic renal insufficiency for the prevention of hepatitis C virus infection. Phase I/II clinical trial, controlled, randomized, blinded, adaptive.
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 14 Oct 2020
Price :
$35
*
At a glance
- Drugs CIGB 230 (Primary)
- Indications Hepatitis C
- Focus Adverse reactions
- 23 Sep 2011 New trial record